(Q33337520)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

Olivier Hequet

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

F Morschhauser

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

P Solal-Celigny

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

F Bouafia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

E Bourgeois

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

C Thieblemont

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

X Leleu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

G Salles

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

B Coiffier

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

language of work or name

English

0 references

publication date

1 June 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

772-778

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11380469%20AND%20SRC:MED&resulttype=core&format=json

Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Acute myocardial infarction following gemcitabine therapy--a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Nucleoside transport and its significance for anticancer drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Fatal pulmonary toxicity resulting from treatment with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Gemcitabine for relapsed or resistant lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2001.02795.X